Molecular Partners signed a collaboration agreement with Roche covering the DRP technology for a variety of undisclosed applications. Under this agreement, Molecular Partners will select DARPins to a variety of different targets, which will be provided by Roche. Roche will carry out further analyses and development. The targets and further financial terms of the agreement were not disclosed.
DARPins constitute a novel class of binding proteins based on Molecular Partners’ designed repeat protein (DRP) technology. Due to their small size and outstanding affinity, selectivity, and stability profiles, as well as their favorable production properties in bacteria, DARPins are one of the most promising non-antibody scaffolds for in vitro and in vivo applications, according to the company.